Is eradication of Helicobacter pylori the feasible way to prevent gastric cancer? New evidence and progress, but still a long way to go

Journal of the Formosan Medical Association

Volumn 107, Issue 8, 2008, Pages 591-599

  Lee, Yi Chia ^a,b   Lin, Jaw Town ^a,c   Chen, Tony Hsiu Hsi ^b   Wu, Ming Shiang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

Cancer prevention; Cost effectiveness; Helicobacter pylori; Stomach neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DISEASE ACTIVITY; ERADICATION THERAPY; GENETIC SUSCEPTIBILITY; HEALTH ECONOMICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; NONHUMAN; PEPTIC ULCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SOCIOECONOMICS; STOMACH CANCER; VACCINATION;

EID: 52949093449     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60176-X     Document Type: Review

References (68)

1. Hamilton SR, Aaltonen LA. eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000.
2. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: Current evidence and practice. Lancet Oncol 2008;9:279-87.
3. Clayton D, Hills M, eds. Statistical Models in Epidemiology. New York: Oxford University Press, 1993.
4. International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Helicobacter pylori. In: Schistosomes, Liver Flukes, and Helicobacter pylori. Lyon: International Agency for Research on Cancer, 1994:177-240.
5. Huang JQ, Sridhar S, Chen Y, et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
6. Eslick GD, Lim LL, Byles JE, et al. Association of Helicobacter pylori infection with gastric carcinoma: A meta-analysis. Am J Gastroenterol 1999;94:2373-9.
7. Xue FB, Xu YY, Wan Y, et al. Association of H. pylori infection with gastric carcinoma: A meta-analysis. World J Gastroenterol 2001;7:801-4.
8. Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: A meta-analysis. Am J Gastroenterol 2007;102:1789-98.
9. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007;56:772-81.
10. Forman D, Graham D. Impact of Helicobacter pylori on society: Role for a strategy of "search and eradicate". Aliment Pharmacol Ther 2004;19(Suppl 1):S17-21.
11. Watanabe T, Tada M, Nagai H, et al. Helicobacter pylori infection induces gastric cancer. Gastroenterology 1998;115:642-8.
12. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived stem cells. Science 2004;306:1568-71.
13. Chang YJ, Wu MS, Lin JT, et al. Helicobacter pylori-induced invasion and angiogenesis of gastric cancer is mediated by COX-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175:8242-52.
14. Chang YJ, Wu MS, Lin JT, et al. Mechanisms for Helicobacter pylori CagA-induced cyclin D1 expression that affect cell cycle. Cell Microbiol 2006;8:1740-52.
15. Natsumoto Y, Marusawa H, Kimohita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007;13:470-6.
16. Fox JG, Wang TC. Inflammation, atrophy and gastric cancer. J Clin Invest 2007;117:60-9.
17. Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut 2005;54:735-8.
18. Parsonnet J, Harris RA, Hack HM, et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996;348:150-4.
19. Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999;159:142-8.
20. Harris RA, Owens DK, Witherell H, et al. Helicobacter pylori and gastric cancer: What are the benefits of screening only for the CagA phenotype of H. pylori? Helicobacter 1999;4:69-76.
21. Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: A Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559-68.
22. Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003;10:148-56.
23. Wang Q, Jin PH, Lin GW, et al. Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis. Zhonghua Liu Xing Bing Xue Za Zhi 2003;24:135-9.
24. Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007;16:875-85.
25. Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer 2000;3:9-18.
26. Gail MH, You WC, Chang YS, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: Design issues and initial data. Control Clin Trials 1998;19:352-69.
27. You WC, Brown LM, Zhang L, et al. Randomized doube-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83.
28. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti- Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
29. Ruiz B, Garay J, Correa P, et al. Morphometric evaluation of gastric antral atrophy: Improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001;96:3281-7.
30. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-40.
31. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study. Gastroenterology 2000;119:7-14.
32. Zhou L, Sung JJ, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003;116:11-4.
33. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: Results of a randomized trial on Helicobacter pylori eradication. Gut 2004;53:1244-9.
34. Moayyedi P, Feltbower R, Crocombe W, et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 2000;14:719-28.
35. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomized controlled trial. Leeds HELP Study Group. Lancet 2000;355:1665-9.
36. Ford AC, Forman D, Bailey AG, et al. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2005;129:1910-7.
37. Lane JA, Harvey RF, Murray LJ, et al. A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population study design and response rates of the Bristol Helicobacter Project. Control Clin Trials 2002;23:321-32.
38. Lane JA, Murray LJ, Noble S, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter Project: Randomized controlled trial. BMJ 2006;332:199-204.
39. Harvey RF, Lane JA, Murray LJ, et al. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophaeal reflux: Bristol Helicobacter Project. BMJ 2004;328:1417-20.
40. Guo HQ, Guan P, Shi HL, et al. Prospective cohort study of comprehensive prevention to gastric cancer. World J Gastroenterol 2003;9:432-6.
41. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004;291:187-94.
42. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures. Helicobacter 2006;11:418-24.
43. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006;29:109-17.
44. Furuta T, Shirai N, Xiao F, et al. Effect of Helicobacter pylori infection and its eradication on nutrition. Aliment Pharmacol Ther 2002;16:799-806.
45. Nwokolo CU, Freshwater DA, O'Hare P, et al. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003;52:637-40.
46. Konturek PC, Cześnikiewicz-Guzik M, Bielanski W, et al. Involvement of Helicobacter pylori infection in neurohormonal control of food intake. J Physiol Pharmacol 2006;57(Suppl 5):67-81.
47. Wu MS, Lee WJ, Wang HH, et al. A case-control study of association of Helicobocter pylori infection with morbid obesity in Taiwan. Arch Intern Med 2005;165:1552-5.
48. Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis. Ann N Y Acad Sci 2007;1108:594-602.
49. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90.
50. Suerbaum S, Micheiti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
51. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 2007;21:281-97.
52. Wu MS, Chen CJ, Lin JT. Host-environmental interactions: Their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1878-82.
53. Lu H, Yamaoka Y, Graham DY. Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol 2005;21:653-9.
54. Ramsey S. Gut check: Can cost-effectiveness analysis help eliminate gastric cancer in Asia. Cancer Epidemiol Biomarkers Prev 2007;16:873-5.
55. Kwon DH, Dore MP, Kim JJ, et al. High-level beta-lactam resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:2169-78.
56. Raghunath A, Hungin AP, Wooff D, et al. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: Systematic review. BMJ 2003;326:737-43.
57. McColl KE. Helicobacter pylori and oesophageal cancer - not always protective. Gut 2007;56:457-9.
58. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24.
59. El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: Critical role of H. pylori. Gastroenterology 2000;118:22-30.
60. Sheu BS, Yang HB, Sheu SM, et al. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin Cancer Res 2003;9:5245-51.
61. Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008;23:351-65.
62. Lai CH, Kuo CH, Chen YC, et al. High prevalence of cagA- and babA2-positive Helicobacter pylori clinical isolates in Taiwan. J Clin Microbiol 2002;40:3860-2.
63. Liu TY, Wu CY, Lin JT, et al. Multistate and multifactorial progression of gastric cancer: Results from community-based mass screening for gastric cancer. J Med Screen 2006;13(Suppl 1):S2-5.
64. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: Results of a randomised controlled trial. Gut 2004;53:12-20.
65. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 2005;35:293-301.
66. Bellack NR, Koehoorn MW, MacNab YC, et al. A conceptual model of water's role as a reservoir in Helicobacter pylori transmission: A review of the evidence. Epidemiol Infect 2006;134:439-49.
67. Queiroz DMM, Luzza F. Epidemiology of Helicobacter pylori infection. Helicobacter 2006;11(Suppl 1):S1-5.
68. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.